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Abstract
Aims/hypothesis γ-Aminobutyric acid (GABA) is a signal-
ling molecule in the interstitial space in pancreatic islets. We
examined the expression and function of the GABA signal-
ling system components in human pancreatic islets from
normoglycaemic and type 2 diabetic individuals.
Methods Expression of GABA signalling system compo-
nents was studied by microarray, quantitative PCR analysis,
immunohistochemistry and patch-clamp experiments on
cells in intact islets. Hormone release was measured from
intact islets.
Results The GABA signalling system was compromised in
islets from type 2 diabetic individuals, where the expression
of the genes encoding the α1, α2, β2a n dβ3G A B A A
channel subunits was downregulated. GABA originating
within the islets evoked tonic currents in the cells. The
currents were enhanced by pentobarbital and inhibited by
the GABAA receptor antagonist, SR95531. The effects of
SR95531 on hormone release revealed that activation of
GABAA channels (GABAA receptors) decreased both
insulin and glucagon secretion. The GABAB receptor an-
tagonist, CPG55845, increased insulin release in islets
(16.7 mmol/l glucose) from normoglycaemic and type 2
diabetic individuals.
Conclusions/interpretation Interstitial GABA activates
GABAA channels and GABAB receptors and effectively
modulates hormone release in islets from type 2 diabetic
and normoglycaemic individuals.
Keywords γ-Aminobutyricacid.Geneexpression.
Humanislets.Type2diabetes
Abbreviations
GABA γ-Aminobutyric acid
qPCR Quantitative PCR
Introduction
γ-Aminobutyric acid (GABA) is an extracellular signal
molecule in the pancreatic islet [1–6]. GAD catalyses the
formation of GABA from glutamate in the beta cells where
GABA is present in both the cytoplasm and vesicles [1, 6].
Once released, GABA is thought to act in an auto- and para-
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DOI 10.1007/s00125-012-2548-7crine manner on the islet cells to modulate hormone secre-
tion [7, 8]. The effective interstitial physiological concen-
tration of GABA in islets is not known. Keeping the proper
levels may be critical for balancing the insulin and glucagon
secretion. Interstitial GABA may also have a role in main-
taining beta cell mass [9, 10].
GABA activates GABAA receptors and the GABAB re-
ceptor in the plasma membrane of alpha, beta and delta cells
[8, 11–14]. The GABAA receptors are pentameric ion chan-
nels (GABAA channels) and normally contain three types of
subunit: 2αs, 2βs and a third type of subunit. To date, 19
different mammalian GABAA subunits (α1-6, β1-3, γ1-3,
δ, ε, π, θ and ρ1-3) have been cloned [15, 16]. Evidence for
the existence of a multitude of GABAA channel subtypes
comes from pharmacological studies. It has been shown
that, for example, benzodiazepine-site ligands can differen-
tiate between GABAA channel subtypes based on the type
of α and γ subunits in the channel complex [16]. Studies
with ligands such as GABA and general anaesthetics have
further confirmed and extended the list of GABAA channel
subtypes [16]. The heterogeneity of channel subunits not
only results in differential response to drugs but also in a
range of physiological properties such as variable channel
conductance and kinetics [16, 17]. The response to GABA
can be further modulated by intracellular proteins and
factors that are associated with the channel complex
[16, 17]. In contrast, there is only one type of GABAB
receptor, which is a G-protein-coupled receptor composed
of two homologous subunits, GABABR1 and GABABR2
[18]. The GABAB1 subunit binds GABA, whereas the
GABAB2 subunit is responsible for Gi/o-protein-coupled
activation [19].
The GABAA channels have been best studied in the brain
and can be classified into two main groups, synaptic and
extrasynaptic channels, based on their location on neurons
and physiological and pharmacological characteristics [16,
17, 20]. Synaptic channels are located in the postsynaptic
membrane, respond rapidly and are activated by millimolar
concentrations of GABA, whereas extrasynaptic channels
are located outside of synapses, are activated with a latency
of minutes and are saturated by submicromolar GABA
concentrations [17, 20]. In the islets, GABA is released by
synaptic-like microvesicles [1], by exocytosis together with
insulin from the large-dense core vesicles [8], by kiss-and-
run exocytosis [8] or by a non-vesicular process [6, 21].
Only in the vicinity of the vesicular release site on the beta
and delta cells can the GABA concentration be expected to
be in the tens of micromolar to millimolar range [1, 8] and
activate transient (phasic), synaptic-like GABAA currents.
Elsewhere, the low interstitial concentrations of GABA
may generate long-lasting (tonic) currents by activating
extrasynaptic-like GABAA channels in the islet cells similar
to that recorded in neurons [20]. If GABA modulates the
electrical activity of the islet cells, then the spatial and
temporal relative concentration of GABA in the endocrine
pancreas has the potential to modulate hormone secretion in
the islets and thereby may contribute to the pathogenesis of
type 2 diabetes if the GABA concentration fluctuations fall
outside of the normal range [4]. Recently, Braun et al
showed that many of the 19 GABAA channel subunits are
expressed in human pancreatic islets [8]. Here we extend the
search to profile the expression of the GABA signalling
system in pancreatic islets obtained from individuals with
or without type 2 diabetes. We demonstrate that the
GABAA channel subunits, α1, α2, β2a n dβ3, are
downregulated in islets from individuals with type 2
diabetes. We also show that the interstitial GABA con-
centration in intact human islets activates GABAA chan-
nel currents, which are increased by pentobarbital.
Hormone secretion is altered in islets from individuals
with type 2 diabetes but can be enhanced with GABAA
and GABAB antagonists.
Methods
Human tissue Islets from cadaver donors were provided
by the Nordic Islet Transplantation Programme (www.
nordicislets.org). Islets were obtained from 54 non-diabetic
donors (25 female, 29 male; mean±SD: age 59±9 years,
BMI 25.9±3.5, HbA1c 5.5±1.1% [37±11 mmol/mol] and
days of culture 3.5±1.9) and nine type 2 diabetic donors
(four female, five male; mean±SD age 57±4 years, BMI
28.5±4.5, HbA1c 7.2±1.1%, (55±11 mmol/mol) and days
of culture 3.3±1.5). Purity of islets was measured by dithi-
zone staining and varied from 57±19% in the type 2 dia-
betic islets to 67±17% in the non-diabetic islets (p00.15).
We also tried to obtain an estimate of the contribution of
exocrine and endocrine tissue by measuring expression of
pancreatic lipase, α2a m y l a s ea n dc h y m o t r y p s i n2 ,a s
markers of exocrine tissue, and somatostatin and glucagon,
as markers of endocrine tissue (probes for insulin were not
on the Affymetrix chip). Using this approach, we found that
the contribution of endocrine tissue did not differ between
non-diabetic and type 2 donors (72±12% vs 68±10%, p0
0.29). We also measured insulin content as a surrogate
marker for beta cell mass in pancreatic islets from hyper-
glycaemic and normoglycaemic donors and observed only a
modest insignificant decrease in insulin content in islets
from hyperglycaemic vs normoglycaemic donors (4.8±3.2
vs 5.6±3.2; p00.4). To obtain a measure of the contribution
of beta and alpha cells in hyperglycaemic and normoglycae-
mic individuals, we calculated the ratio between MafA, a
beta cell marker, and MafB, an alpha cell marker; this ratio
did not differ between hyperglycaemic and normoglycaemic
donors (43±13% vs 38±12%, p00.1). Only hand-picked
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physiological experiments. The islets were cultured in
CMRL 1066 (ICN Biomedicals, Costa Mesa, CA, USA)
supplemented with 10 mmol/l HEPES, 2 mmol/l L-glutamine,
50 μg/ml gentamicin, 0.25 μg/ml Fungizone (Gibco,
Gaithersburg, MD, USA), 20 μg/ml ciprofloxacin (Bayer
Healthcare, Leverkusen, Germany) and 10 mmol/l nicotin-
amide at 37°C (5% CO2, vol./vol.) for 1–9 days before being
used in experiments. All procedures were approved by the
ethics committees at Uppsala and Lund Universities, and
informed consent was obtained by appropriate measures
from donors or their relatives.
Total RNA isolation Total RNA was isolated from islets
using the AllPrep DNA/RNA Mini Kit (Qiagen, Hilden,
Germany). RNA concentration and quality were measured
using a NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA) and Experion RNA
gel chips (Bio-Rad, Hercules, CA, USA), respectively. RNA
from sorted human pancreatic islet beta cells was kindly
provided by Dr Cilio, Lund University.
Microarray gene expression The microarrays were per-
formed following the Affymetrix standard protocol as
previously described [22] (see electronic supplementary
material [ESM] text).
Quantitative PCR (RT-qPCR) Gene expression profiling of
the GABA signalling system components in human islet
was performed on total RNA by RT-qPCR as previously
described [9] (see ESM text). The primer sequences are
shown in ESM Table 1.
Immunofluorescence staining Immunofluorescence staining
of human islets was performed as previously described [23]
(see ESM text).
Current recordings from cells in intact islets All patch-
clamp recordings were performed at room temperature
(20–22°C) on intact islets. Drugs used were purchased from
Sigma-Aldrich (Stockholm, Sweden) or Ascent Scientific
(Weston-Super-Mare, UK). The positive modulator, pento-
barbital, and the GABAA antagonist, SR95531, were dis-
solved in the extracellular solution. For the whole-cell
voltage-clamp recordings, islets were perfused with an ex-
tracellular solution containing in mmol/l: 126 NaCl, 5.6
KCl, 2.6 CaCl2, 1.2 MgCl2 and 10 HEPES, pH 7.4 . The
pipette solution contained in mmol/l: 125 CsCl, 30 CsOH,
10 EGTA, 1 MgCl2, 5 HEPES, pH 7.2. Recordings were
made at the holding potential of −70 or −90 mV. The single-
channel recordings were performed in the whole-cell patch-
clamp configuration. Patch pipettes were made from boro-
silicate glass and had a resistance of 5–8M Ω when filled
with the pipette solution. Patch-clamp current recordings
were carried out using an Axopatch 200B amplifier, filtered
at 2 kHz, digitised online at 10 kHz using an analogue-to-
digital converter and analysed with pClamp software
(Molecular Devices, Sunnyvale, CA, USA).
Glucose-stimulated hormone secretion in human islets
Secretion of insulin or glucagon in human islets stimulated
by glucose was measured by the standard protocol as pre-
viously described [24] (see ESM text).
Statistical analysis Data are presented as mean±SEM. Dif-
ferences in expression levels were analysed by Student’s t
test or non-parametric Mann–Whitney test. Correlations
were analysed using non-parametric Spearman’s tests. In
all tests, p<0.05 was considered significant. All statistical
tests were performed using SPSS version 18.0 software
(SPSS, Chicago, IL, USA) or Sigma Plot version 11 (Systat
Software, San Jose, CA, USA).
Results
Expression of genes encoding the GABA signalling system
components in islets A comprehensive expression profile of
genes encoding proteins participating in the GABA signal-
ling cascade in excitable cells was created using cDNA
microarray from islets from 54 non-diabetic donors (ESM
Fig. 1a, b). Of the genes encoding the GABAA channel
subunits, the β3, γ2, δ, ε, π and ρ2 subunits were most
prominently expressed in the islets (ESM Fig. 1a). High
expression signals were also detected for GABARAP
(GABA receptor-associated protein), radixin (RDX), the
NKCC1 transporter (SLC12A2)a n dGAD65 (also known
as GAD2) (ESM Fig. 1b).
We further examined and compared gene expression in
islets from individuals with and without type 2 diabetes
using RT-qPCR analysis (Fig. 1). The highest level of ex-
pression was obtained for the genes for α1, α2, β3, γ2, π
and ρ2 GABAA channel subunits in islets from normogly-
caemic individuals (n014). In islets from type 2 diabetic
donors, the α1, α2, β2a n dβ3 GABAA subunits were
significantly downregulated (Fig. 1a). The other genes in
the GABA signalling cascade (Fig. 1b) were all similarly
expressed and did not differ significantly between islets
from individuals with type 2 diabetes and those from nor-
moglycaemic donors. We further examined whether we
could detect downregulation of genes in the islets from
hyperglycaemic donors (not diagnosed with type 2 diabetes;
n06). Only the α2G A B A A channel subunit was significantly
downregulated in islets from hyperglycaemic individuals
compared with normoglycaemic individuals (Fig. 1c, α1,
p00.127; β2, p00.536; β3, p00.386).
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in human pancreatic islets To determine which specific
GABAA channel subunits are present in pancreatic islet beta
cells, we analysed expression of the subunits in sorted beta
cells from one normoglycaemic donor using RT-qPCR. The
α1, α2, α5, β3, γ2, δ, π and ρ2 GABAA channel subunits
were present in the cells (Fig. 2a). To identify the cellular
and subcellular location of the GABAA channel subunits,
we immunostained for the α1o rα2 subunits together with
insulin and glucagon in pancreatic islets (Fig. 2b–e). The
results show that, in human pancreatic islets, the α1 and the
α2G A B A A channel subunit proteins are present in the
plasma membrane and cytoplasm of alpha and beta cells.
The α2 subunit appears particularly prominent in the cells,
whereas α1 expression is more limited.
Interstitial GABA activates GABAA channel currents in
intact islets The exact interstitial GABA concentration in
the islets is not known, but can be assumed to be in the
submicromolar range or similar to that in the extracellular
fluid in the brain [25]. The highest GABA concentration is
expected to be around the beta cell release sites. Using the
patch-clamp technique and recording from cells in intact
islets, we examined currents from GABAA channels acti-
vated by the interstitial GABA originating within the islets,
as no GABA was added experimentally. Figure 3a shows
whole-cell currents, which were inhibited by the GABAA
channel competitive antagonist, SR95531 (100 μmol/l). The
upward shift in the baseline current when SR95531 was
applied shows the level of the GABA-activated GABAA
current. The levels of lines 1 and 2 in Fig. 3a correspond
to the peak values (Fig. 3b) of Gaussian fits to histograms of
30 s current records from before and after SR95531 appli-
cation. The difference between the peak values was 4.4 pA
and is the level of the GABA-generated current in the cell.
This type of current is termed ‘tonic’, as it is long lasting and
can significantly affect cell excitability [20]. In two cells,
synaptic-like transient currents were recorded (data not
shown) similar to that reported by Braun et al [1, 8]. We
examined whether larger tonic currents were generated if we
applied no glucose to the cells, but applied 10 mmol/l gluta-
mine. Under these conditions, no tonic currents were
recorded (n05), but when we applied 20 mmol/l glucose
to islets from the same donor, tonic currents were evoked
(n03). We then examined whether a positive modulator of
GABAA channels, pentobarbital, enhanced the GABA-
generated tonic currents (Fig. 3c, d). The level of line 3
(Fig. 3c) corresponds to the peak value (Fig. 3d)o ft h e
Gaussian fit to a histogram of 30 s current record after
100 μmol/l pentobarbital application to the islet. The level
of the GABA-generated tonic current in the cell was 3.6 pA
and was enhanced to 7.1 pA by 100 μmol/l pentobarbital
(Fig. 3d). Interestingly, GABA-generated tonic currents
Fig. 1 Gene expression of GABA signalling system components in
human islets determined by RT-qPCR. a In islets from normoglycae-
mic donors (grey bar, n014) and donors with type 2 diabetes (black
bar, n09), 18 out of 19 GABAA channel subunits were detected, with
the most prominent expression level for α1, α2, β3, γ2, π and ρ2. In
islets from individuals with type 2 diabetes, expression of the α1, α2,
β2 and β3 GABAA channel subunits was significantly downregulated
compared with normoglycaemic donors. b Gene expression of GABA
signalling system accessory proteins, receptors, enzymes and
transporters from normoglycaemic donors (grey bar, n014) and donors
with type 2 diabetes (black bar, n09). The most prominent expression
was detected for GEPHRYN, GABARAP, RADIXIN, GAD65 and the
chloride transporter, NKCC1 (also known as SLC12A2). c In islets
from hyperglycaemic donors (open bar, n06), expression of the α2
GABAA channel subunit was downregulated compared with normo-
glycaemic donors (grey bar, n014). The relative expression of each
target gene was normalised to reference gene ACTB using the 2ΔCt
method. All individual experiments were run in duplicate, and the data
presented as mean±SEM. Differences in expression levels were
analysed by Student's t test: *p<0.05, **p<0.01, ***p<0.001
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donors until we applied pentobarbital (n05, Fig. 3e, f). The
results are consistent with pentobarbital enhancing GABAA
currents by increasing both the open probability and the
channel conductance of GABAA channels, resulting in
higher apparent affinity of the channels for GABA. The
enhanced current was inhibited by SR95531 (Fig. 3e,f ) .W e
recorded single-channel currents from three different cells
(Fig. 4a, b, c) in islets from normoglycaemic donors
(Fig. 4a, slow time scale (s); Fig. 4a expanded, Fig. 4b and
Fig. 4c, fast time scale (ms); the glucose concentration was
20mmol/landtheholdingpotential:Fig.4a,−90mV;Fig.4b,
−70 mV; Fig. 4c, −70 mV). In all three cells, when the islets
were perfused with 100 μmol/l SR95531, the single-channel
Fig. 2 GABAA channel subunit mRNA expression and protein localisa-
tion in human pancreatic islet alpha and beta cells. aExpression of GABAA
channel subunits in sorted human pancreatic islet beta cells from one
normoglycaemic donor quantified by RT-qPCR. The β3a n dγ2 subunits
were prominently expressed, and the expression of the α1, α2, π and ρ2
subunits was somewhat lower. The relative expression of each target gene
was normalised to the reference gene ACTB using the 2ΔCt method.
b Human islets were co-labelled with antibodies staining insulin (green),
α1G A B A A channel subunit (purple) and glucagon (red). Scale bar, 5 μm.
cHumanislets were co-labelledwith antibodies staininginsulin(green),α2
GABAA channel subunit (purple) and glucagon (red). Scale bar, 5 μm.
d Immunoreactivity of α1 GABAA channel subunit (purple) was detected
in both insulin-positive cells (green) and glucagon-positive cells (red) from
human islets. Scale bar, 5 μm. e Immunoreactivity of α2 GABAA channel
subunit (purple) was detected in both insulin-positive cells (green) and
glucagon-positive cells (red) from human islets. Scale bar, 5 μm
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s) shows SR95531 inhibition of the channels in one of the
cells. The most prominent single-channel current amplitude
recorded in each cell is indicated in Fig. 4 by the dotted lines
and gave channel conductance of 51 pS, 36 pS and 71 pS for
the cells in Fig. 4a, b and c,r e s p e c t i v e l y .
Effects of GABAA channel and GABAB receptor antagonists
on insulin and glucagon secretion in islets from individuals
with or without type 2 diabetes In islets from both normo-
glycaemic and type 2 diabetic donors, 16.7 mmol/l glucose
stimulated insulin secretion and reduced glucagon secretion
relative to the secretion observed in response to 1 mmol/
l glucose (ESM Fig. 2). To study the effects of GABA on
insulin and glucagon release, we examined the effects of the
GABAA and GABAB antagonists, SR95531 (10 μmol/l,
Fig. 5a, b) and CGP55845 (10 μmol/l, Fig. 5c,d ) ,o n
hormone secretion in islets from normoglycaemic and type
Fig. 3 Activation, by interstitial GABA, of GABAA channel currents
that are enhanced by pentobarbital in human pancreatic islets. a A
representative current trace showing GABA-activated tonic current,
recorded from a cell in an intact human islet from a normoglycaemic
donor and activated by interstitial GABA, was inhibited by application
of SR95531 (100 μmol/l), a GABAA channel antagonist, causing a
clear outward shift in the holding current (line 1 to line 2). SR95531
similarly inhibited the baseline current in islet cells in another four
experiments. b Gaussian fits to all-point histograms derived from 30 s
current recordings in (a) before (1) and during (2) application of
SR95531. The difference between the peaks of the Gaussian fits denotes
the mean tonic current (−4.4 pA). c A representative current trace show-
ing that pentobarbital (100 μmol/l) increased the GABA-activated tonic
current(inwardshiftoftheholdingcurrentline1toline3),recordedfrom
acellinanintacthumanisletfromanormoglycaemicdonorandactivated
by the interstitial GABA. The current was then inhibited by 100 μmol/
l SR95531 (outward shift of the holding current line 3 to line 2). Pento-
barbital similarly enhanced the GABA-generated current in islet cells in
another five experiments. d Gaussian fits to all-point histograms derived
from 30 s current recordings in (c) before (1) and during application of
pentobarbital(3)orpentobarbitaltogetherwith SR95531(2).Thepeakof
the Gaussian fits denotes the mean holding currents (1, −3.6 pA; 2, 0 pA;
3, −7.1 pA). e A representative current trace showing that pentobarbital
(100 μmol/l)increasedtheGABA-activated tonic current(inwardshift of
the holding current line 1 to line 3), recorded from a cell in an intact
human islet from a type 2 diabetes donor and activated by the interstitial
GABA. The current was then partially inhibited by 100 μmol/l SR95531
(outwardshiftoftheholdingcurrentline3toline2).fGaussianfitstoall-
point histograms derived from 30 s current recordings in (e) before (1)
and during application of pentobarbital (3) or pentobarbital together with
SR95531 (2). The peak of the Gaussian fits denotes the mean holding
currents (1, 0 pA; 2, −2.1 pA; 3, −16.1 pA). Currents were recorded in
20 mmol/l glucose from cells in intact islets at the holding potential of
−90 mV in the whole-cell patch-clamp configuration. As no GABAwas
added experimentally, the GABA must have originated within the islet
1990 Diabetologia (2012) 55:1985–19942 diabetic individuals incubated with basal (1 mmol/l) or
high-concentration (16.7 mmol/l) glucose.
Figure 5a and c show that insulin secretion was increased
at 1.0 mmol/l but significantly decreased at 16.7 mmol/l
glucose in islets from individuals with type 2 diabetes
compared with islets from normoglycaemic donors. At
1 mmol/l glucose, insulin secretion was increased by a
factor of 1.6 in the islets from type 2 diabetic donors and
was unaffected by either SR95531 (10 μmol/l, Fig. 5a)o r
CGP55845 (Fig. 5c). At 16.7 mmol/l glucose, insulin secre-
tion in islets from the type 2 diabetic individuals was de-
creased by 60% (Fig. 5a), but could be increased about 1.5-
fold with the GABAB receptor antagonist CPG55845
(Fig. 5c) in islets from both type 2 diabetic and normogly-
caemic donors. As 10 μmol/l SR95531 may not completely
inhibit very high-affinity GABAA channels, we examined in
islets from two normoglycaemic individuals whether
100 μmol/l SR95531 had any effect on insulin secretion.
In low (1 mmol/l) glucose, 100 μmol/l SR95531 significantly
increasedinsulinsecretion(1G+SR100μmol/l:0.20±0.03ng
islet
−1 h
−1, n012 from two individuals; 1G: 0.14±0.01 ng
islet
−1 h
−1, n012 from four individuals, p<0.05) to the level
observed for type 2 diabetic individuals (0.23±0.02 ng
islet
−1 h
−1, n012 from three individuals), but failed to modu-
late insulin secretion in 16.7 mmol/l glucose (n012 from two
individuals, data not shown).
Figure 5b and d show that glucagon secretion was only
significantly increased in islets from type 2 diabetic individ-
uals compared with normoglycaemic donors when the islets
were exposed to 16.7 mmol/l glucose. Glucagon secretion
could be enhanced with 10 μmol/l SR95331 (Fig. 5b)i n
islets exposed to either 1 or 16.7 mmol/l glucose, whereas
CGP555845 (Fig. 5d) was without effect. SR95531 in-
creased glucagon secretion at 1.0 and 16.7 mmol/l glucose
by a factor of 1.3 and 1.5, respectively, in islets from type 2
diabetic donors, and a factor of 1.4 and 1.9, respectively,
in islets from normoglycaemic donors. The somewhat
reduced effect of 10 μmol/l SR95531 on islets from type
2 diabetic individuals may be due to the fact that these
islets exhibited increased basal glucagon secretion com-
pared with the normoglycaemic donors. The GABAB
receptor antagonist, CGP55845, did not modulate gluca-
gon secretion at either low or high glucose concentrations
(Fig. 5d). Together these results demonstrate regulation of
hormone release by the GABAA channels and GABAB
receptors.
We further examined whether the mRNA expression of
GABAA channel subunits α1 and α2 in islets correlated
with the HbA1c or insulin secretion of donors. Interestingly,
expression of the GABAA channel subunits, α1 and α2,i n
islets correlated negatively with the HbA1c level of donors
(Fig. 5e, f), and α2, but not α1, correlated positively with
insulin secretion stimulated with 16.7 mmol/l glucose
(Fig. 5e, f).
Discussion
Our results show an active role for the GABA signalling
system in human pancreatic hormone release. Interstitial
GABA released from pancreatic beta cells evokes GABA-
generated currents in intact human islets by activating
GABAA channels expressed in alpha and beta cells. The
currents can be enhanced by the GABAA channel modula-
tor, pentobarbital, and blocked by the specific GABAA
antagonist, SR95531. The α1, α2, β2a n dβ3G A B A A
channel subunit genes are downregulated in islets from type
2 diabetic individuals, whereas other components of the
GABA signalling system are not affected. In islets from
type 2 diabetic and normoglycaemic individuals, the
GABAB receptor antagonist, CPPG55845, increased insulin
release at 16.7 mmol/l glucose, whereas the GABAA chan-
nel antagonist, SR95531, increased glucagon release in both
1 and 16.7 mmol/l glucose.
Fig. 4 Interstitial GABA activates single-channel currents in intact
islets. Single-channel currents that were later inhibited by 100 μmol/l
SR95531 were recorded in three different cells (a, b, c) from normo-
glycaemic donors. a A representative current trace (top trace, slow time
scale, s) showing GABA-activated single-channel currents and inhibi-
tion by 100 μmol/l SR95531. The solid line shows the time when the
extracellular solution containing SR95531 was perfused through the
recording chamber. The broken lines indicate from where in the re-
cording the current trace on the faster time scale (ms) was obtained.
The glucose concentration was 20 mmol/l and the holding potential was
−90 mV (a), −70 mV (b)a n d−70 mV (c). The most prominent single-
channel conductance in the cells in a, b and c was 51 pS, 36 pS and
71 pS, respectively. For all three cells, the currents were recorded in the
whole-cell patch-clamp configuration from cells in intact islets and
were activated by interstitial GABA and inhibited by application of
SR95531 (100 μmol/l)
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were expressed in the islets, with the highest expression
levels detected for the α1, α2, β3, γ2, π and ρ2 subunits.
The results are in good agreement with the results of Braun
et al [8]. Immunostaining of islets confirmed the presence of
α1 and α2 subunits in both the alpha and beta cells. The
Fig. 5 GABAA channel and GABAB receptor antagonists increase hor-
mone release in pancreatic islets from normoglycaemic and type 2 dia-
betic individuals. a Insulin release was increased in 1 mmol/l glucose
(1G) but decreased in 16.7 mmol/l glucose (16.7G) in islets from type 2
diabetic individuals (black bar) compared with those from normoglycae-
mic individuals (grey bar). SR95531, a GABAA channel antagonist, at a
concentration of 10 μmol/l did not modulate insulin release. b Glucagon
release was increased in 16.7 but not 1 mmol/l glucose in islets from type
2 diabetic individuals compared with those from normoglycaemic
donors. SR95531 (10 μmol/l) increased glucagon release at both glucose
concentrations in islets from type 2 diabetic and normoglycaemic indi-
viduals. c Insulin release was increased by the GABAB antagonist,
CGP55845 (10 μmol/l) in 16.7 but not 1 mmol/l glucose in islets from
type 2 diabetic and normoglycaemic individuals. d Glucagon release was
not affected by CGP55845 (10 μmol/l). Grey bars:n019–31fromfour to
six normoglycaemic individuals. Black bars: n019 from three type 2
diabetic donors. Data are presented as mean±SEM; *p<0.05, ***p<
0.001. e Correlation of the α1G A B A A subunit gene expression with
insulin secretion measured at 16.7 mmol/l glucose and HbA1c level. A
negative correlation with HbA1c (black circles; n051; R00.3724; p0
0.0071) and no correlation with insulin (grey circles; n053; R00.1655;
p00.2363) were observed. Correlation analysis was performed using
non-parametric Spearman’st e s t .f Correlation of the α2G A B A A subunit
gene expression with insulin secretion measured at 16.7 mmol/l glucose
andHbA1c level.AnegativecorrelationwithHbA1c (blackcircles;n051;
R00.6453; p<0.0001) and positive correlation with insulin (grey circles;
n053; R00.4790; p00.0003) were observed. Correlation analysis was
performed using non-parametric Spearman’s test. NB To convert values
for HbA1c in % into mmol/mol, subtract 2.15 and multiply by 10.929
1992 Diabetologia (2012) 55:1985–1994GABAA channels contain two αs, two βs and a third type of
subunit in the channel complex. In islets, γ2, π or ρ2 could
each be the third type of subunit in the pentameric channel,
but would confer vastly different pharmacological prop-
erties on the channel [16]. Intriguingly, the high expres-
sion of π and ρ2 subunit genes seen in human islets is
very different from the low and restricted distribution in
the brain [16, 26].
It is likely that a number of different subtypes of GABAA
channels are expressed in the islets and that they differ in their
sensitivity to GABA and other drugs [16]. Whether the dif-
ferent single-channel conductances we recorded in this study
are related todifferentGABAA channel subtypesoractivation
of a specific GABAA channel subtype by different concen-
trations of GABA remains to be determined [20, 27].
Glucose modulated GABAA channel gene expression is in
agreement with previous reports [14], but, in contrast with
mice, stimulation with highglucose concentration reduced the
α2G A B A A channel subunit mRNA level in human islets.
The glucose effect on expression was even stronger in islets
fromtype2diabeticindividuals,inwhomnotonlyα2butalso
α1, β2a n dβ3G A B A A channel subunit expression was
decreased comparedwithisletsfromnormoglycaemicdonors.
Inisletsfromtype2diabeticandnormoglycaemicindividuals,
we further compared gene expression of proteins that might
modify the function of the GABA signalling system in the
islets [17, 28]. These proteins included: (1) the GABAB re-
ceptor subunits; (2) the intracellular proteins, gephyrin and
radixin, involved in plasma membrane clustering of GABAA
channels; (3) GABARAP and HAP1, which take part in
transport or recycling of the channels; (4) GAD65 and
GAD67, which make GABA from glutamate; (5) GABA
transporters (GAT1-3, BGT1), which transport GABA over
the cell plasma membrane; and (6) transporters such as
NKCC1 and KCC2, which determine the intracellular chlo-
ride concentration and thereby determine whether open-
ing of the GABAA channels will cause depolarisation or
hyperpolarisation of the cells. None of these proteins
was differentially expressed in islets from non-diabetic
or type 2 diabetic individuals.
It is well established that GABA can activate GABAA
channels in pancreatic islets, but so far it has not been shown
that the interstitial GABA concentration that exists within
the islets is sufficient to activate the native channels [8, 12].
In recent years, evidence has emerged that extrasynaptic-
like GABAA channels can be supersensitive to GABA,
being activated by GABA concentrations in the picomolar
to nanomolar range [20, 27]. Activation of the channels
induces long-lasting (tonic) currents in neurons that modu-
late the cellular excitability [17, 29, 30]. In this study of
intact human islets, interstitial GABA generated tonic
currents in the cells. As no GABA was added, the GABA
must have originated from cells within the islets.
Furthermore, since the GABA-activated current was en-
hanced by pentobarbital, the interstitial GABA concentra-
tion must have been sub-saturating [31]. Whether the
reduced level of GABAA channel subunits, the decreased
extracellular GABA, or both resulted in the reduced tonic
current in the islets from the type 2 diabetic donors remains
to be determined. Expression levels for the GABA trans-
porters were low in the islets. In the brain, these transporters
are essential for removing GABA from the synapse to avoid
inactivation of the GABAA channels [32], but may not
be needed in the islets, as small molecules diffuse down
their concentration gradient and enter the blood in the
highly vascularised islets.
At low (1 mmol/l) glucose, basal GABA inhibits insulin
secretionbyactivatingGABAAchannelsexpressedinthebeta
cells. The finding that a saturating concentration (100 μmol/l)
of the antagonist, SR95531, was required to increase the
insulin release is consistent with either very high-affinity
GABAA channels and/or higher local GABA concentrations
in the vicinity of beta cells. How the inhibition comes about
may berelated todecreased openprobability ofCa
2+channels
bysubthreshold depolarisations ofthe membrane potential for
channel activation [33]o rag e n e r a le f f e c to fv o l t a g e -
dependent inactivation of channels involved in action poten-
tial firing [34]. At 16.7 mmol/l glucose, the GABAB antago-
nist CPG55845 increased insulin release by a factor of 1.5 in
islets from both normoglycaemic and type 2 diabetic individ-
uals. These results indicate that the mechanism by which
GABAB receptors modulate insulin secretion was intact in
islets from type 2 diabetic individuals. They are also in agree-
ment with the unchanged expression levels of GABAB recep-
tor subunits in islets from type 2 diabetic donors.
Conclusions The GABA signalling system is compromised
in pancreatic islets from type 2 diabetic individuals. The α2
GABAA channel subunit is already downregulated in islets
from hyperglycaemic individuals, and, as the disease
progresses to type 2 diabetes, expression of the α1, β2a n d
β3 GABAA channel subunit genes also decreases. TheGABA
released within the islets normally activates GABAA channels
and the GABAB receptor, which modulate insulin and gluca-
gon release. The GABA signalling system is an integral part of
a system in human islets maintaining glucose homeostasis.
Characterising the functional and pharmacological properties
of the GABAA channel subtypes expressed in alpha and beta
cells may reveal new specific targets for drugs aimed at mod-
ulating hormone release.
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